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cidence and prevalence reported.  Main Results: Eight stud-
ies met the criteria (3 on motor neurone disease; 4 on Hun-
tington’s disease; 1 on progressive supranuclear palsy). The 
incidence of motor neurone disease ranged from 1.06 to 
2.4/100,000 person-years. The prevalence ranged from 4.02 
to 4.91/100,000. The prevalence of Huntington’s disease 
ranged from 4.0 to 9.94/100,000. The prevalence of progres-
sive supranuclear palsy ranged from 3.1 to 6.5/100,000.  Con-
clusions: The review updates the incidence/prevalence of 
long-term neurological conditions. Future epidemiological 
studies must incorporate comprehensive case ascertain-
ment methods and strict diagnostic criteria. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Progressive neurological diseases vary in presentation, 
both in timescale and severity. This review forms part of 
a Policy Research Programme commissioned by the Na-
tional Institute for Health Research to assess disease bur-
den on service user, family and health and social care 
services. The investigated conditions were requested by 
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 Abstract 
 Background: Updated, robust estimates of the incidence 
and prevalence of rare long-term neurological conditions in 
the UK are not available. Global estimates may be misrepre-
sentative as disease aetiology may vary by location.  Objec-
tives: To systematically review the incidence and prevalence 
of long-term neurological conditions in the UK since 1988. 
 Search Strategy: Medline (January 1988 to January 2009), 
Embase (January 1988 to January 2009), CINAHL (January 
1988 to January 2009) and Cochrane CENTRAL databases. 
 Selection Criteria: UK population-based incidence/preva-
lence studies of long-term neurological conditions since 
1988. Exclusion criteria included inappropriate diagnoses 
and incomprehensive case ascertainment.  Data Collection 
and Analysis: Articles were included based on the selection 
criteria. Data were extracted from articles with ranges of in-
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the commission to encompass a range of aetiologies, 
symptoms, diagnoses and prognoses.
 Rationale and Aim of Review 
 The aim was to systematically identify and update the 
incidence and prevalence of the following long-term neu-
rological conditions:
 • Motor neurone disease 
 • Huntington’s disease 
 • Progressive supranuclear palsy 
 • Multiple system atrophy 
 • Postpolio syndrome 
 • Charcot-Marie-Tooth disease 
 • Dominantly inherited ataxias 
 Knowledge of these data is valuable in informing fu-
ture research and health service policies.
 Methods 
 The review protocol is accessible at http://www.ltnc.org.uk/
research_files/RESULT_study.html. Population-based studies of 
incidence and prevalence were sought.
 Scoping Search 
 A scoping search identified existing reviews of incidence and 
prevalence. Existing reviews would be updated, not repeated. 
Medline (Ovid; 1950 to week 2 of 2009], Embase (Ovid; 1980 to 
week 46 of 2008], CINAHL (Ovid; 1982 to week 1 of 2009], the 
Science Citation Index, Cochrane Library (CENTRAL) and Cen-
tre for Reviews and Dissemination databases were searched. 
 Main Search Strategy 
 The search strategy (Appendix 1) identified articles from Med-
line, Embase and CINAHL. The Cochrane Library (CENTRAL) 
and databases of ongoing research and unpublished literature were 
also searched. Reference lists of included articles were assessed to 
capture further articles omitted from the search strategy.
 Inclusion/Exclusion Criteria 
 Articles were included based on the criteria outlined in  table 1 . 
Comprehensive case ascertainment was required in order to en-
sure maximum patient capture. Studies before 1988 were exclud-
ed as the review aimed to present up-to-date statistics. Strict di-
agnostic criteria were set to minimise bias from misdiagnoses. 
Inclusion was based on agreement between 2 of the independent 
reviewers (T.H., J.C., G.J., J.R.). In cases of non-consensus, a third 
independent review was obtained. In cases of incomprehensive 
study methodology, authors were approached to determine a 
study’s potential inclusion.
 Data Extraction 
 The following data were extracted into tables:
 • Source: authors and journal published 
 • Study design: e.g. cross-sectional, cohort, etc. 
 • Population denominator 
 • Timescale: incidence time frame and prevalence date 
 • Case ascertainment method 
 • Diagnostic method 
 • Outcome: incidence per 100,000 person-years; prevalence per 
100,000 of population  
 • Methodological limitations 
 • Potential bias 
 Data Analyses 
 Incidences were reported as ranges. Pooling statistics was not 
possible due to methodological heterogeneity and shared popula-
tion denominations between certain studies.
 Results 
 Existing Systematic Reviews 
 No existing systematic reviews of incidence and prev-
alence were identified.
 Study Yield 
 The initial search yielded 8,869 references; 311 were 
identified as potentially relevant. Of these, 9 met the in-
clusion criteria and were included in the review ( fig. 1 ). 
 Included Studies by Condition 
 Motor Neurone Disease (Amyotrophic Lateral 
Sclerosis) 
 Five studies assessed the incidence/prevalence of mo-
tor neurone disease ( table 2 ). Total population coverage 
was 11,498,075, although some overlap between studies 
emerged. The incidence of motor neurone disease in the 
UK ranged from 1.06 to 2.4/100,000 person-years (in-
Table 1. S election criteria
Study design
– Population-based observational studies with a defined
population denominator
– Comprehensive case ascertainment including steps to
maximise the number of cases captured (e.g. multiple patient 
registers at multiple centres searched)
– Study conducted after 1988 (pre-1988 research would not 
provide recent statistics)
Population
– Persons with the long-term conditions of interest diagnosed 
by the criteria specified below1
– Resident in the UK
Outcomes
– Prevalence/incidence of long-term conditions in the UK
1  Diagnostic criteria available in Appendix 2.
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cluding all diagnostic categories of the World Federation 
of Neurology, WFN, and El Escorial criteria). The preva-
lence ranged from 4.02 to 4.91/100,000 of the populations 
studied.
 Huntington’s Disease 
 Three studies assessed the prevalence of Huntington’s 
disease ( table 3 ). No reports of incidence were identified. 
Total population coverage was 5,483,871. The prevalence 
ranged from 4.0 to 6.4/100,000 of the populations studied. 
 Progressive Supranuclear Palsy 
 One study assessed the prevalence of progressive su-
pranuclear palsy ( table 4 ). The study included 3 substud-
ies. A national study of the entire UK population, a re-
gional study covering a catchment of 2,598,240 and a 
community study covering a catchment of 259,998 peo-
ple. The prevalence ranged from 1.0/100,000 in the na-
tional study to 6.5/100,000 in the community study. 
However, only the community study had a comprehen-
sive case ascertainment and we therefore report these sta-
tistics in our results.
 Results Summary 
 Table 5 illustrates a summary of results identified in 
the study.
 Excluded Studies 
 Four studies illustrated in  table 6 were excluded from 
the review.
Articles yielded from initial
search strategy: n = 8,869
Articles retained for further
review: n = 311
Articles retained for further
review: n = 30
Articles retained for further
review: n = 13
Articles included in review: n = 9
 motor neurone disease: n = 5
 Huntington‘s disease: n = 3
 Charcot-Marie-Tooth disease: n = 0
 progressive supranuclear palsy: n = 1
 multiple system atrophy: n = 0
 postpolio syndrome: n = 0
 dominantly inherited ataxias: n = 0
Excluded – not studies of long-term
neurological conditions of interest:
n = 8,558
Excluded – not incidence/prevalence
studies of conditions of interest:
n = 281
Excluded – study published 
before 1988: n = 17
Excluded – inclusion criteria not
fulfilled: n = 4
 Fig. 1. Flowchart of included/excluded
articles. 
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Table 3. D etails of included studies
Source/
condition
Design Population/
denominator
Timescale Case ascertainment 
method
Diagnostic 
method
Outcome Potential bias/
methodological
limitations
Morrison
et al.
(1995) [6]
HD
Population-
based study 
of 
prevalence
Northern Ireland
population of 
1,569,971 based 
on 1991 national 
census
Prevalence 
estimated on 
April 21, 1991
Northern Ireland 
GP records; neurolo-
gist, psychiatrist and 
geriatrician records; 
Department of Medical 
Genetics diagnostic 
 records
DNA-confirmed 
diagnoses for all 
patients
Prevalence of 
6.4/100,000
Small founder effect 
due to large families; 
however, families not 
large enough to cause 
bias in population
statistics
James
et al.
(1994) [7]
HD
Population-
based study 
of 
prevalence
South and Mid 
Glamorgan, and 
Gwent; 
population of 
1,393,900 based 
on 1991 national 
census
Prevalence esti-
mated on 
March 1, 1994
HD register for South 
Wales
Details of
formal diagnosis 
in  register; 
notes of
symptom type 
and onset
provided
Prevalence of 
6.2/100,000
All known living cases 
of HD studied;
potential for cases not 
included in register, 
and subsequent 
underestimation of 
prevalence
Watt and
Seller
(1993) [8]
HD
Population-
based study 
of 
prevalence
Oxford Region 
Health Authority 
under NHS; 
population of 
2,520,000 
Prevalence 
estimated on 
live patients on 
January 1, 1988
Oxford region medical 
genetics department 
records; 
it is thought by the time 
of the study all persons 
affected in 1988 would 
have been referred and 
ascertained
Confirmed by 
presymptomatic 
linkage test
Prevalence of 
4.0/100,000
None identified
HD = Huntington’s disease; NHS = National Health Service; GP = general practitioner.
Table 4. D etails of included studies
Source/
condition
Design Population/
denominator
Timescale Case ascertainment
method
Diagnostic 
method
Outcome Potential bias/
methodological
limitations
Nath
et al.
(2001) [9]
PSP
Popula-
tion-
based 
study of 
preva-
lence
3 substudies; 
– National study: 
population of 59,236,500
– North East study:
population of 2,589,240
– Community study
(35 GP catchments in 
Newcastle-upon-Tyne):
population of 259,998; 
populations all based on 
1998 census figures for 
the UK
Preva-
lence on 
January 1, 
1999
– National study:
case ascertainment not 
complete
– Regional study: direct 
referral of cases from all 
neurologists in the region, 
correspondence reviews, 
database screening, 
inpatient hospital sources
– Community study: 
screening of GP records for 
potential patients followed 
by review of records and 
structured interview and 
clinical examination
Possible or 
probable 
cases based 
on 
NINDS-
SPSP crite-
ria
– National study:
prevalence of 
1.0/100,000
– Regional study: 
prevalence of 
3.1/100,000
– Community 
study:
prevalence of 
6.5/100,000
Smaller population 
denominator at each 
level of study led to 
more extensive capture 
methods, hence the 
greater prevalence in 
smaller denomination 
studies; 
national study did not 
use active case ascertain-
ment methods and 
thought up to 81% of 
cases unidentified
PSP = Progressive supranuclear palsy; GP = general practitioner; NINDS-SPSP = National Institute of Neurological Disorders and Society for
Progressive Supranuclear Palsy.
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 Unreported Conditions 
 No articles relating to postpolio syndrome, Charcot-
Marie-Tooth disease, multiple system atrophy and domi-
nantly inherited ataxias in the UK were identified that 
met the inclusion criteria. However, some studies were 
identified that did not meet the required criteria. Whilst 
it would be inappropriate to include these studies in the 
results,  table 7 provides incidence and prevalence statis-
tics for excluded studies in conditions not represented in 
the results to provide at least some information on these 
conditions. However, one must view these results with 
caution due to the associated methodological limitations.
 Discussion 
 The review aimed to systematically report the inci-
dence and prevalence of long-term neurological condi-
tions in the UK. Review findings and the variation be-
tween studies are discussed.
 Motor Neurone Disease 
 Some variation in incidence is evident. An incidence 
of 1.06/100,000 person-years was found in South East 
England  [1] , compared to 2.4 in Scotland  [2] . Differences 
in age structure between geographical locations may in-
fluence variations in incidence and prevalence rates. The 
literature suggests that onset generally occurs after 40 
years age, with a peak incidence between 55 and 75 years 
 [14, 15] . Data from the 2001 census  [16, 17] indicate that 
32% of the population of Greater London are over 45 
years of age compared to 40% of the Scottish population. 
Furthermore, approximately 10% of the Greater London 
population are in the 60- to 75-year age bracket com-
pared to 14% in Scotland. Such statistics are likely to 
make small differences in incidence and prevalence rates 
but would not account for any large differences. Other 
than these geographical considerations, there is no evi-
dence of environmental factors to explain differences. 
Familial cases are reported as less than 10%, making it 
unlikely that geographical clustering of families with 
motor neurone disease affected observed figures. Meth-
odological differences within the study design may ex-
plain observed differences. Omissions of small numbers 
of unidentified cases could influence rates reported sub-
stantially. However, case ascertainment and diagnostic 
methods appear similar, and differences could be attrib-
utable to chance.
 The prevalence was consistent across studies, ranging 
from 4.02 to 4.91/100,000. These figures sit at the lower 
end of the reported global prevalence (4–10/100,000)  [18–
22] . However, it is worth noting that the actual prevalence 
may be higher as those without a diagnosis are not in-
cluded in these estimates.
 Huntington’s Disease 
 The prevalence ranged from 4.0 to 6.4/100,000. This is 
contrary to reported global rates (0.4–0.5/100,000), but 
comparable to the prevalence reported in other Western 
countries (8–10/100,000)  [23] .
 Differences in prevalence between studies could be at-
tributable to geographical variation due to the hereditary 
nature of the disease. A previous study reported a preva-
lence of 9.94/100,000 in the Grampian region of Scotland 
in 1987  [13] , compared to 4.0/100,000 in Oxfordshire in 
1993  [8] . Authors report the Grampian region to have low 
migration levels due to thriving local communities, com-
pared to relatively high migration in the Oxfordshire re-
gion. A closed gene pool population compared to a popu-
lation with high migration rates may explain such dis-
crepancies.
 The possibility of methodological differences between 
studies remains and could be a factor in reported discrep-
ancies. Case ascertainment appears consistent between 
the studies. However, some studies used a genetic test as 
a diagnostic confirmation  [6] , whereas others appeared to 
assess records and registers for diagnostic confirmation 
 [7] . Consequently, in studies using genetic testing, posi-
tive diagnoses were made for presymptomatic patients, 
which was not possible in studies where only symptom-
atic patients were included. As mentioned previously, in 
rare conditions incomplete case ascertainment or disease 
misclassification can skew the reported incidence/preva-
lence significantly in both directions.
Table 5.  Ranges of prevalence/incidence of the long-term condi-
tions
Incidence range, 
cases per
100,000
person-years
Prevalence 
range, cases per
100,000
of population
Motor neurone disease 1.06–2.4 4.02–4.91
Huntington’s disease not reported 4.0–6.4
Progressive supranuclear palsy not reported 6.5
Multiple system atrophy not reported not reported
Dominantly inherited ataxias not reported not reported
Charcot-Marie-Tooth disease not reported not reported
Postpolio syndrome not reported not reported
 Incidence and Prevalence of Rare
Long-Term Neurological Conditions 
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 Progressive Supranuclear Palsy 
 Evidence suggests progressive supranuclear palsy is 
sporadic. Tau gene mutations have been identified as a 
predisposition. However, two thirds of the global popula-
tion possess this polymorphism. Consequently, other 
factors may be more important in progressive supranu-
clear palsy.
 The prevalence ranged from 1.0/100,000 in the nation-
al study by Nath et al.  [9] to 6.5/100,000 in the commu-
nity study by the same authors. However, the authors ad-
Table 6. E xcluded studies
Disease Reason for exclusion
Craig et al.
(2005) [10]
Dominantly inherited 
ataxias
Incomprehensive case ascertainment: investigation of a cohort of families with 
undiagnosed ataxias and suspected Huntington’s disease; there may be additional 
cases outside the cohort studied, hence incomplete case ascertainment
Craig et al.
(2004) [11]
Dominantly inherited 
ataxias
Incomprehensive case ascertainment: investigation of already clinically affected 
families; no broader searches, therefore possibility of further cases in families not 
studied, hence incomplete case ascertainment possible
Schrag et al.
(1999) [12]
Multiple system
atrophy/progressive 
supranuclear palsy
Incomprehensive case ascertainment: 33/202 patients (16%) identified as potential 
progressive supranuclear palsy/multiple system atrophy patients declined to be 
assessed further, therefore complete case ascertainment was not possible; estimates
of incidence/prevalence are likely to be too low
Simpson and
Johnston (1989) [13]
Huntington’s disease Although study published after 1988, data refer to pre-1988 incidence and prevalence
Table 7.  Details of excluded studies of conditions not represented in the review
Source/
condition
Design Population/
denominator
Timescale Case ascertainment 
method
Diagnostic method Outcome
Schrag
et al.
(1999) [12]
MSA/PSP
Population-
based study 
of incidence 
and 
prevalence
15 general 
practices from 
a linkage 
scheme in the 
London region; 
population of 
121,608
Prevalence 
on July 1, 
1997
Computerised records 
screened, with deliberate 
overascertainment to
include all possible cases; 
neurologist reviewed
eligible records and
excluded where
appropriate; 241 eligible 
patients, 202 agreed to be 
assessed for diagnosis
Computerised records 
reviewed;
neurological interview 
and assessment 
including question-
naires and video to 
capture neurological 
symptoms; 
longitudinal assess-
ments to identify
developing symptoms 
of conditions
– PSP: 5 diagnosed with probable PSP 
and 1 possible PSP; crude prevalence
of 4.9/100,000 (95% CI: 1.8–10.7); 
probable only cases – prevalence of 
4.1/100,000
– MSA: 2 diagnosed with probable 
MSA, 1 possible MSA; crude prevalence 
of 3.3/100,000 (95% CI: 0.9– 8.4); 
probable only cases – prevalence of 
1.6/100,000
Craig
et al.
(2004) [11]
SCA6
Population-
based study 
of 
prevalence
North-east 
government 
region; 
population of 
2,516,500
Prevalence 
on June 30, 
2001
SCA6 families identified 
and studied
Molecular genetic and 
haplotype analyses
32 affected individuals from 16 
genealogically distinct families; DNA 
only available for 26; 
minimum prevalence of 1.59/100,000 
(95% CI: 1.04–2.14) in population aged 
over 16 years, and of 3.18/100,000 (95% 
CI: 2.08–4.28) in those >45 years old
Craig
et al.
(2005) [10]
SCA17
Population-
based study 
of 
prevalence
North-east 
government 
region; 
population of 
2,516,500
Prevalence 
on June 30, 
2001
192 families with 
undiagnosed ataxia
and 90 families with 
suspected Huntington’s 
disease studied
Molecular genetic and 
haplotype analyses
2 patients identified with CAG 
expansion greater than control; each 
had an affected sister;
minimum prevalence of 0.16/100,000 
(95% CI, upper value: 0.31)
MSA = Multiple system atrophy; PSP = progressive supranuclear palsy; SCA = spinocerebellar ataxia.
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mit the case ascertainment was not ‘active’ and fully com-
prehensive due to the denominator size and report that 
81% of the cases may be unascertained based on the com-
munity study prevalence. The regional study fits within 
the reported global prevalence range (1.39–5.8/100,000) 
 [24–26] . As the condition is sporadic, the greater preva-
lence observed in the community study is probably due 
to a more complete case ascertainment.
 General Points 
 A fundamental point is that the incidence and preva-
lence reported should be regarded as minimum figures. 
Assuming studies had 100% case ascertainment of diag-
nosed patients, the statistics would still omit undiag-
nosed patients. Consequently, such studies will under-
predict incidence and prevalence. One could argue that 
due to the lack of firm diagnostic criteria, diagnoses may 
switch between conditions, resulting in under- and over-
estimation of figures. However, misclassifications and 
changes in diagnoses would have insignificant bearing 
on statistics in comparison to the magnitude of effect of 
an exclusion of undiagnosed patients.
 Non-Reported Conditions 
 No studies of the incidence/prevalence of Charcot-
Marie-Tooth disease or postpolio syndrome were identi-
fied. In Charcot-Marie-Tooth disease, this was surpris-
ing as it is reported as the most prevalent condition in 
global studies  [27] . Furthermore, one may expect more 
extensive research with follow-up in a non-life-limiting 
condition. With regard to postpolio syndrome, despite a 
number of intervention trials  [28–33] , the lack of report-
ed incidence/prevalence may reflect difficulties in con-
firming diagnoses due to the symptoms being similar to 
those associated with natural ageing. Accurate case as-
certainment would be difficult and expose statistics to 
bias.
 Conclusion 
 In conclusion, the review reported incidence/preva-
lence ranges for the long-term neurological conditions 
from all identified studies in the UK since 1988. The 
rates varied between studies, particularly for Hunting-
ton’s disease, possibly attributable to geographical varia-
tion. The exclusion of articles due to methodological 
limitations suggests future epidemiological studies re-
quire comprehensive case ascertainment and strict and 
standardised diagnostic methods. Such safeguards will 
ensure more comprehensive reviews of incidence and 
prevalence, covering a wider denominator population of 
the UK.
 Appendix 1 
Medline (Ovid) 1950 – week 2, 2009 
1 exp Huntington’s Disease
2 exp Motor Neurone Disease
3 exp Amyotrophic Lateral Sclerosis
4 exp Multiple System Atrophy
5 exp Postpoliomyelitis Syndrome
6 exp Charcot-Marie-Tooth Disease
7 exp Hereditary Motor and Sensory Neuropathies
8 exp Supranuclear Palsy, Progressive
9 spinocerebellar ataxia
10 episodic ataxia
11 dentatorubropallidoluysian atrophy
12 DPRLA
13 long-term neurological conditions.mp.
14 progressive neurological conditions.mp.
15 progressive neurological disease.mp.
16 exp Epidemiology
17 exp Incidence
18 exp Prevalence
19 exp Diagnosis
20 exp Prognosis
21 or/1–15
22 or/16–20
23 21 and 22
24 limit 23 to (English language and yr = “1988–2009”)
Embase (Ovid) 1980 – week 46, 2008
1 exp Huntington’s Disease
2 exp Motor Neurone Disease
3 exp Amyotrophic Lateral Sclerosis
4 exp Multiple System Atrophy
5 exp Postpoliomyelitis Syndrome
6 exp Charcot-Marie-Tooth Disease
7 exp “Hereditary Motor and Sensory Neuropathies”
8 exp Supranuclear Palsy, Progressive
9 spinocerebellar ataxia
10 episodic ataxia
11 dentatorubropallidoluysian atrophy
12 DPRLA
13 long-term neurological conditions.mp.
14 progressive neurological conditions.mp.
15 progressive neurological disease.mp.
16 exp Epidemiology
17 exp Incidence
18 exp Prevalence
19 exp Diagnosis
20 exp Prognosis
21 or/1–15
22 or/16–20
23 21 and 22
24 limit 23 to (English language and yr = “1988–2009”)
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Appendix 2
Diagnostic criteria
– Motor neurone disease: diagnosed by the El Escorial criteria 
[34] after 1994, and the WFN criteria before 1994 (definite, 
probable, possible and suspected categories)
– Huntington’s disease: diagnosed by genetic test and/or pres-
ence of physical and psychological symptoms; confirmed by at 
least 1 neurologist
– Progressive supranuclear palsy: diagnosis confirmed by at least 
1 neurologist
– Multiple system atrophy: diagnosis confirmed by at least 1 neu-
rologist
– Postpolio syndrome: confirmation of polio virus in earlier life, 
and presence of symptoms
– Charcot-Marie-Tooth disease: diagnosis confirmed by family 
history and neurological tests
– Dominantly inherited ataxias: diagnosis by genetic and neuro-
logical tests
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